Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Because they announced the next podcast two weeks after the end of a quiet period. The shorts feast here on extended silence by management. It will likely rebound some prior to the 31sr podcast but if there is not any substantial news then they will just pull it right back down. Been the pattern for the past two years. The clock is ticking on liquidity events. They must deliver by end of year.
This post aged well.
When you say being honest does that imply at other times you are not honest? Just wondering. Seen this in two of your posts today. I am always skeptical of peoples motives when they start with being honest with you.
That’s cute.
So what will rhyme with AMEX. It ain’t stinky.
Makes sense to manage risk. If someone thinks it is going to .008 why aren’t they selling their 3 million shares currently owned to then re enter at .008. That would be a logical moved based on what some are saying here. Think that will happen? Hell no it won’t happen. He’s holding.
Don’t you need to know when the RS will occur to buy right before it? We will likely wake up one morning and the RS and uplist will be done.
Can’t help but wonder whether some here are talking gloom and doom so people will sell so they can scoop up their cheap shares. Some will fall for this tactic and regret it later. The company will be a $25M cap after the RS and uplist. That is the only number I care about. The upside on the cap is big if what they have in metformin plays out like many here feel it may. After all isn’t that why you are still here?
Probably a misspelled word. If you look at his previous posts he got it right.
So for the third time today I will state that have never said what the value of the company is. Stop putting words in my mouth.
With that said I am glad to see it pushing .0024.
It doesn’t matter. Predictions like this are just attention grabbers. Nothing is going to happen. LOL.
$100 post split is equivalent to $.36 pre split. I would take that ROI any day based on my average cost. We all have different objectives.
$100 price post split off a $8.25 price would be about a 1100% gain. It does not need to go $100 post split to make good money here. Do you know how the market cap of a company is derived?
Na, I don’t think I will need to.
So you don’t think they will upgrade, is that correct? I say that so when they do upgrade you will be sure to admit you were wrong.
You have no idea what you’re talking about. How will there be a lot more “cheapies” (whatever that means) after a RS? The stock will be a lot thinner and any positive news will move the stock higher.
I believe the comment about the office was a tad tongue in cheek. Gotta have a sense of humor around here.
I don’t disagree with you on the $1M loan terms. However, it did give them the runway to get the CRADA in place and work through the animal trials.
As for IR and PR, it seems they announce material news when they have it. They don’t seem to be the type to post just anything to move a stock so the flippers can do their thing. This management group is not beholden to people who threaten to sell their shares if they don’t do what people want. They seem to be more focused on developing their pipeline, mainly getting Metformin to a liquidity event.
Not sure who you are speaking about putting their money where their mouth is, but it I have a few million shares. My hunch is that the proponents of the company on this board have the shares they want. Besides that I am waiting to add when they get to that $.01 level you say they are heading to.
Great article for those who have not read this. Dr. Chew, who is the lead investigator on the CUBT animal trials currently in week 11, is the doctor quoted here in talking about AMD patients moving away from monthly injections. The treatment discussed here, while effective, has complications surrounding it.
Now I understand why Dr. Chew had an interest in being the lead investigator on the CUBT Metformin trials. The article gave me goose bumps quite frankly. This is a hidden gem people. And Dr Bharti, also from the NEI, is the inventor of the Metformin eye drop solution and on the CUBT board of advisors. Connect the dots. And right now this company is only a $18M market cap. Ridiculously low.
https://consumer.healthday.com/1-24-some-patients-with-macular-degeneration-could-stop-monthly-eye-injections-2656425654.html
Totally agree. I am willing to take the risk for the potential reward. The wet AMD market is $11B annually. And the number of people who have dry AMD is probably 10x the number of wet AMD patients. If the Metformin solution proves to slow the progression of dry to wet AMD then this will be a homerun and big pharma will come knocking. And the one thing bears conveniently ignore is the fact that the Metformin IP inventor is Dr. Kapil Bharti, who works for the NEI and sits on the CUBT Advisory Board and the lead investigator of the animal trials, and who will compile the IND data, is world renowned researcher Dr. Emily Chew from the NEI.
Yep that is exactly right. And they will convert prior to the RS then be subject to RS ratio. By my estimate that will be about 180M shares added to the current OS count. Market cap about $24M after RS without knowing the terms of the other financing or offering. In the grand scheme the potential for the metformin eye drop to treat AMD will dwarf the post RS and uplist valuation.
Some quick math here. It is my understanding that there are 30M preferred shares which upon conversion would convert to 30% of the current OS or approx. 180M shares on top of the current 600M shares outstanding. That would put us at about 800M shares of common stock all of which would then be subject to the RS ratio. At the current .03 price that would give us a market cap of about $24M going into further funding and uplist. Sure there will be tradable warrants etc. which will hold price back for a period of time. However with a 5M OS float any good news, which I would expect shortly thereafter, will move the price.
I am looking at this toward Q1 at which point they should have information on human trials. If they show efficacy in the human trials the value of the eye drop solution will be a lot of $$$$ imo. I’m holding and will be patient here.
Sctts you and I will be filing it out for those $.01 shares. I would buy as many as I possibly could.
I know. I subscribe to the board.
I’m sure Ken reads posts here. He can do with this information as he likes. And I will continue to provide my input when I see the inconsistencies.
Shouldn’t news of any kind be made available to all shareholders, not just to those on a board? Especially if it material news.
They did say that. This is not the first time they have said they were going to have announcements and did nothing. They need to clean this up. Don’t say one thing and do another. You lose credibility when you do things like this. If they say they are going to have more news or announcements in a given time period, they should damn well do what they said. Really tired of this type of nonsense.
I’m thinking 175:1 RS ratio. I don’t think they price this as a $155 stock with a 5,000:1 ratio. Just my opinion of course.
This is a true statement. No one can guarantee price after a split. They are simply stating a risk like all companies do in their filings.
Yes it has. Nothing has changed since they announced they would be doing the split. People just trying to stir the pot on false statements. They will not be doing a 10,000:1 RS. Period.
Why do you say that? What in the S1 leads to that conclusion?
More like a 12 week trial and 30 day review. About the same total time. By my count we should be in week 10 of the 12 week trial. September probably a good estimate.
Does anyone know the significance of having this many tokens mined? What is the impact on the business, whether it be in generating revenues, moving the company toward a liquidity event or helping the TBIs? Just trying to understand the measurable impact on the business and how this should be driving share prices as Ken mentioned here.
Totally agree. The story here is all about market cap based on their pipeline. As it stands now it is less than $18M. If the animal studies of the Metformin eye drop prove effective, then moves to human trials following the IND, then the question to Conix point is what is the value of the Metformin eye drop. Hard to predict but significantly higher than an $18M cap is a given. It is all about the current solutions in the market (injections). Who on earth would not trade an injection into the eye for an eye drop? Everyone! The market potential for a prescription eye drop to treat eye disease is massive.
I don’t disagree with you. An 80:1 ratio would be better. I just don’t see them releasing material news that would get it to $.10 before all this happens. I could be wrong that is just my opinion.
For those late to the party here, below is the original Press Release from the company announcing the grant of the exclusive worldwide rights from the NIH for the repurposing of Metformin to treat degenerative eye disease. Dr. Kapil Bharti, who is on the CUBT Advisory Board, is the inventor of the IP. Dr. Emily Chew, one of the world’s most renowned eye researchers, was assigned as the lead NEI investigator of the animal trials. Kudos to CUBT Chairman Paul Michael’s for seeing and jumping on this opportunity.
https://curativebiotech.com/connectyx-announces-grant-of-exclusive-worldwide-license-from-national-institutes-of-health-for-repurposing-metformin-to-treat-degenerative-eye-disease
In this release Michael’s stated, “The Company anticipates being prepared for human testing of this reformulation by third quarter of 2022.” He estimated this time frame 2/4/21, right in the middle of the pandemic. Considering they are now in the 9th week of animal trials and likely a couple months away from filing the IND, they appear to be right on track with Paul’s original time estimate, quite an accomplishment given the supply chain issues and staffing challenges at governmental agencies faced during the pandemic.
They seem to be right on track. My estimate is a 150:1 RS ratio on the RS. This, along with the raise and uplist will provide necessary funding to not only drive the Metformin solution to the finish line but also fund the advancement of the other three drugs in their pipeline to treat brain cancer, rabies, and immune compromised kidney patients. It will also bring new institutional $ since many can’t buy OTC.
Know what you own! I ain’t going anywhere.
Looks like they have an interim CFO. Hopefully they are making progress with their human trials.
Randy, isn’t Nelson still with QSAM? You mentioned that he is no longer with the company? We’re you speaking of QSAM or another company?
Lots of research going on in this space. And CUBT owns the worldwide rights to the Metformin eye drop solution invented by Dr. Bharti who works at the National Eye Institute, and who is on the CUBT Board of Advisors. Dr. Chew, a leading researcher in the world from the NEI, is the lead investigator on the Metformin animal trials. Wonder if Chew and Bharti are talking as she works through the current animal trials. Yeah, they’re talking. This asset has a lot of value. The potential here is massive.
Conix, I got your PM. Can’t reply because I don’t pay here. Thanks for the information. Very interesting.
The NIH has entered into many licensing agreements over the years. What they are doing with CUBT is very common. They will receive a royalty from future product sales. They receive well over $100M a year in royalties from the many licensing agreements they have in place.
Because many, if not most of the technologies developed at the NIH and FDA, are early stage biomedical technologies, the time and development risks to develop a commercial product are high. That is why they collaborate and enter into relationships like the Cooperative Research and Development Agreement they did with CUBT, which owns the worldwide licensing rights of the Metformin eye drop solution, which has huge potential in the multi Billion Dollar AMD treatment market.
It is highly unlikely the National Institute of Health and more specifically the National Eye Institute would have entered into this CRADA with CUBT if they did not see a potential revenue stream through future royalties.
Non dilutive? Not so sure about that. What would that look like? And what is the plan to get it over $.10 before hand. Please
Share what you know.